



OpenEMR

February 17, 2016

by

ViSolve Inc.,

6559, Springpath Lane, San Jose, California 95120, USA

Email: services@visolve.com

Table of Contents

1. ViSolve Introduction..... 3

2. Scope of the Proposal 3

3. Effort Guesstimate 4

MU3 Analysis & Estimation by ViSolve

1. ViSolve Introduction

ViSolve is a niche consulting and custom software development organization with high value onshore and remote teams with years of experience in Healthcare, Cloud and Open Source Technologies. Established in 1995, ViSolve is headquartered in San Jose, California with an offshore development center in India with 50+ Engineers and led by a group of Industry Veterans and Seasoned Professionals with a flair for Healthcare IT, Cloud/Virtualization and Open Source. With 15+ years of experience in Open Source solutions customization, development and support, ViSolve is one of the leading contributors to the open source community. It has built, released and supported over 60 Open Source products for a leading system vendor in the world and migrated over 160 healthcare practices to Amazon Cloud (AWS).

ViSolve has strong relationship with HP/ VMWare's product development, QA, Performance, Global pre-sales teams and specializes in Product development, Build, Performance, QA and support of applications and kernel modules on VMware, HP-UX, Linux platforms.

As a Board Member of OpenEMR, ViSolve has contributed significantly to the development of OpenEMR. ViSolve's team possesses in-depth experience in OpenEMR and Interoperability (HL7/DICOM Integration). ViSolve has been working with a leading academic medical center based in NY for the past two years in providing interoperability and customized EMR solutions.

2. Scope of the Proposal

The scope of this proposal is to present an effort guesstimate required for OpenEMR to attain Meaningful Use Stage III certification. In this proposal, it is assumed that OpenEMR has achieved 2014 edition complete Meaningful Use certification. The Effort Guesstimate table in Section 3 details the available functionality today and what is needed to be done down the road, in order to achieve Meaningful Use Stage III certification.

3. Effort Guesstimate

This table details the approximate effort required for OpenEMR to achieve Meaningful Use Stage III certification.

Note:

- In this proposal, it is assumed that OpenEMR has achieved 2014 edition complete Meaningful Use Certification (Stage II).
- Features that are marked 'Gap Eligible' are those that were covered during Meaningful Use Stage II certification. Hence they need not be tested again during Stage 3 certification.

| MU Regulation Citation | Criterion | Gap Eligibility | Estimate | Comments |
|------------------------|--|-----------------|------------|---|
| § 170.315(a)(1) | Computerized provider order entry (CPOE) – medications | GAP Eligible | | |
| § 170.315(a)(2) | CPOE – laboratory | GAP Eligible | | |
| § 170.315(a)(3) | CPOE – diagnostic imaging | GAP Eligible | | |
| § 170.315(a)(4) | Drug-drug, drug-allergy interaction checks for CPOE | GAP Eligible | | |
| § 170.315(a)(5) | Demographics | | 1 Day | |
| § 170.315(a)(6) | Problem list | | 1-2 Weeks | |
| 170.315(a)(7) | Medication list | GAP Eligible | | |
| 170.315(a)(8) | Medication allergy list | GAP Eligible | | |
| 170.315(a)(9) | Clinical decision support | | 1 Month | |
| 170.315(a)(10) | Drug-formulary and preferred drug list checks | GAP Eligible | | |
| 170.315(a)(11) | Smoking status | GAP Eligible | | |
| 170.315(a)(12) | Family health history | | | Will be taken care when problem list is implemented |
| 170.315(a)(13) | Patient-specific education resources | | 2 Days | Need to remove HL7 standard information for lab results |
| 170.315(a)(14) | Implantable device list | | 3 Weeks | |
| 170.315(a)(15) | Social, psychological, and behavioral data | | 2 Weeks | |
| 170.315(b)(1) | Transitions of care | | 2-3 Months | |

| | | | | |
|--------------------|---|--------------|------------|--|
| 170.315(b)(2) | Clinical information reconciliation and incorporation | | 1 Month | |
| 170.315(b)(3) | Electronic prescribing | | 2-4 Weeks | Currently OpenEMR uses third party application Newcrop for eRX. We may need to integrate their API as per new requirements |
| 170.315(b)(4) | Common Clinical Data Set summary record – create | | 2-4 Weeks | |
| 170.315(b)(5) | Common Clinical Data Set summary record – receive | | 1 Month | |
| 170.315(b)(6) | Data export | | 2-3 Weeks | |
| 170.315(b)(7) | Data segmentation for privacy – send | | 2-3 Weeks | |
| 170.315(b)(8) | Data segmentation for privacy – receive | | 2-3 Weeks | |
| 170.315(b)(9) | Care plan | | 1 Week | |
| 170.315 (c)(1)-(3) | CQM | | 2 Months | |
| 170.315(d)(1) | Authentication, access control, authorization | GAP Eligible | | |
| 170.315(d)(2) | Auditable events and tamper-resistance | | 2-4 Weeks | |
| 170.315(d)(3) | Audit report(s) | GAP Eligible | | |
| 170.315(d)(4) | Amendments | GAP Eligible | | |
| 170.315(d)(5) | Automatic access time-out | GAP Eligible | | |
| 170.315(d)(6) | Emergency access | GAP Eligible | | |
| 170.315(d)(7) | End-user device encryption | GAP Eligible | | |
| 170.315(d)(8) | Integrity | | 2 Weeks | |
| 170.315(d)(9) | Trusted connection | | 2 Weeks | |
| 170.315(d)(10) | Auditing actions on health information | | | Optional |
| 70.315(d)(11) | Accounting of disclosures | GAP Eligible | | |
| 70.315(e)(1) | View, download, and transmit to 3 rd party | | 1-2 Months | |
| 170.315(e)(2) | Secure messaging | | 1 Week | |

| | | | | |
|-----------------|--|--|------------|--|
| 170.315(e)(3) | Patient health information capture | | 2 Weeks | |
| 170.315(f)(1) | Transmission to immunization registries | | 1 Month | |
| 170.315(f)(2) | Transmission to public health agencies – syndromic surveillance | | 3-4 Weeks | |
| § 170.315(f)(3) | Transmission to public health agencies – reportable laboratory tests and value/results | | 1-2 Months | |
| 170.315(f)(4) | Transmission to cancer registries | | 3-4 Weeks | |
| 170.315(f)(5) | Transmission to public health agencies – electronic case reporting | | | May not be required since EP need to report any 3 out of 7 reports |
| 170.315(f)(6) | Transmission to public health agencies – antimicrobial use and resistance reporting | | | |
| 170.315(f)(7) | Transmission to public health agencies – health care surveys | | | |
| 170.315(g)(1) | Automated numerator recording | | | Covered as part of Automated measure calculation |
| 170.315(g)(2) | Automated measure calculation | | 2-3 Months | |
| 170.315(g)(3) | Safety-enhanced design | | | Documentation |
| 170.315(g)(4) | Quality system management | | | Documentation |
| 170.315(g)(5) | Accessibility-centered design | | | Documentation |
| 170.315(g)(6) | Consolidated CDA creation performance | | | Covered as part of Transition of Care |
| 170.315(g)(7) | Application access – patient selection | | 2 Weeks | |
| 170.315(g)(8) | Application access – data category request | | 1 Week | |

| | | | | |
|---------------|--|--|---------|---------------------------------------|
| 170.315(g)(9) | Application access – all data request | | 1 Week | |
| 170.315(h)(1) | Direct Project | | 1 Week | Covered as part of Transition of Care |
| 170.315(h)(2) | Direct Project, Edge Protocol, and XDR/XDM | | 2 Weeks | Covered as part of Transition of Care |

Total Effort Required (Approximate) - 31 Engineering Months

Disclaimer

Whilst every effort has been made to ensure the accuracy of all information and statements contained in this document, the functionality and capabilities referred to are best practices only, based on the general understanding of ViSolve Consultants. ViSolve is not liable for Errors and Omissions and end-users can use this guide at their own risk. The contents of this document are subject to change without notice. The development, release, and timing of any features or functionality in this document remain at the sole discretion of ViSolve Inc. All copyrights and trademarks are the property of their respective owners.